CysC和RBP联合测定在肿瘤化疗患者早期肾损伤监测中的应用

Combination of Cystain C and RBP to detect early renal fuction impairment caused by cancer chemotherapy

目的探讨血清半胱氨酸蛋白酶抑制剂C(CystainC,CysC)和视黄醇结合蛋白(Retinol-Binding,RBP)联合测定在肿瘤化疗患者早期肾损伤监测中的应用。方法对照组60例,为健康体检无肾脏病史,且尿蛋白定性为阴性者;试验组为27例肿瘤化疗患者,检测BUN、Crea、CysC、RBP四个指标,并进行统计学分析。结果 BUN浓度对照组为(3.4±1.12)mmol/L,试验组为(4.44±1.38)mmol/L;Crea浓度对照组为(69.04±20.77)μmol/L,试验组为(80.33±26.23)μmol/L;CysC浓度对照组为(0.85±0.13)mg/L,试验组为(1.70±0.49)mg/L;RBP浓度对照组为(48.21±14.3)mg/L,试验组为(82.59±14.08)mg/L。结论联合检测血清CysC和RBP对检测肿瘤化疗患者早期肾损伤具有较高的临床应用价值。

Objective To discuss the role of combination ofCystain C and RBP in detecting early renal function impairment caused by cancer chemotherapy. Methods 60 patients in control group, without kidney proteinuria in physical examination; 27 cases in experimental group, with cancer chemotherapy, and the value of BUN, Crea, CysC, RBP were reviewed retrospectively. Results The concentration of urea was （3.4± 1.12） mmol/L in control group, （4.44± 1.38） mmol/L in the experimental group; the concentration of creatinine was （69.04±20.77） μmol/L in the control group, （80.33±26.23） μmol/L in the experimental group; the concentration of CysC in the control group was （0.85±0.13） mg/L, （1.70±0.49） mg/L in the experimental group; the concentration of RBP was （48.21=14.3） mg/L in the control group, （82.59± 14.08） mg/L in the experimental group. Conclusion Combination of Cystain C and RBP has high clinical value in detecting early renal function impairment caused by cancer chemotherapy.